Healx will analyze proprietary Sanofi compound data using Healx’s AI-driven drug discovery platform to generate therapeutic rationale. November 13, 2024 07:00 AM Eastern Standard Time.

In addition to its pharma partnership, Healx is also working on its own pipeline of medicines. This past August, the company raised $47 million in a Series C round that was co-led by R42 Group and ...

Sanofi last week closed its purchase of an early-stage immunology drug candidate from Dren Bio for up to $1.9 billion and in May agreed to acquire Vigil Neuroscience for about $470 million, adding ...

Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding co-led by Europe’s Atomico and Silicon Valley-based R42.. The ...

Sanofi's Focus On Alzheimer's Disease The companies expect the deal to close in the third quarter. In addition to the $470 million, Vigil shareholders will receive a contingent value right, or CVR ...

CAMBRIDGE, England, November 13, 2024--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease ...

Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI ...